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Achieving gender equity in clinical trials requires that women be included in sufficient 
numbers to carry out analysis, that those sub-sample analyses be carried out, and that 
results be communicated in such a way as to expand medical knowledge, inform policy 
decisions and educate patients.  In this article, we examine the extent to which Canada 
promotes gender equity through its laws and guidelines, viewed within the context of its 
drug safety system and its research ethics board structure. We analyze the structuring of 
information by the pharmaceutical industry and consider the impact of its promotional 
activities on the state of gender knowledge and health.  In the final section we propose 
ways to improve the structuring of health information to promote gender equity. 
 
     
 
I Introduction 
The case for inclusion of women in clinical trials has been well made since the 1980s.1 A number 
of considerations inform the need for sex and gender inclusion in the clinical trial process.  Most 
importantly, unless drugs are tested on the entire population that will use them once the drug is 
on the market, we cannot be satisfied that health and safety have been adequately protected.  A 
study of trials and meta-analyses of drug therapies for myocardial infarction published in five 
leading medical journals between 1992 and 1996 reveal that women were poorly represented 
(mean: 24%), and that just under a third (32%) of 42 reports reviewed provided results based on 
gender, while even fewer (12%) discussed the differences between men and women.2  
Cardiovascular disease is the leading cause of death of women in Canada and globally. 
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Analysis of the data for individual sub-groups is essential to increasing our knowledge of a 
drug’s effects.  A study of clinical trials of Vioxx found that more women than men had been 
included (74 per cent were women) but that 80 per cent of the trials included no description of 
the drug’s efficacy by sex. Only one trial reported adverse effects data by sex.3  This study also 
notes that in the Spanish trials of Vioxx, 78 per cent of the reported side effects of Vioxx were 
found in women.4  Further support for gender inclusion is found in the clear evidence of sex-
based differences in pharmacokinetics and pharmacological effect (pharmacodynamics).5  These 
results have implications for dosage as well as the impact of the drug.  For example, one post-
market study on paroxetine (Paxil/Seroxat) notes “the complete lack of coherent science-based 
advice on dosage…[which] is essential for the safe and effective use of most drugs, but is 
available for few.”6 
 
The need for women’s health research has been amply demonstrated through the Women’s 
Health Initiative [WHI], the first longitudinal study of women’s health.  Starting in 1991, the 
WHI carried out a fifteen year program of research through clinical trials and an observational 
study on leading causes of death and disability among postmenopausal women: cardiovascular 
disease, cancer, and osteoporosis.7  Their clinical trial of hormone replacement therapy 
challenged conclusions about its benefits and risks, and led significant numbers of women to 
stop the therapy.8  Similarly, their study on long-term aspirin use revealed a differential impact 
on heart health as between men and women.9 
 
By the 1990s women’s activists had become concerned about the lack of representation of 
women in clinical trials and research.  Women’s health became the subject of international 
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agreement at the United Nations Fourth World Conference on Women in Beijing in 1995. 10  The 
Declaration produced at the Conference guarantees, among other things, equal access and 
treatment to men and women in education and health care.  Canada adopted the Beijing 
Declaration and established The Federal Plan for Gender Equality in the same year.  The 
Federal Plan called for research into participation in clinical trials and research.  Health Canada 
also created a guideline on inclusion in clinical trials in 1997.11  Meanwhile, the federally funded 
research councils added a non-exclusion clause on the basis of sex to the Tri-Council Policy 
Statement, Ethical Conduct for Research Involving Humans [TCPS].12  In the first part of this 
article, we will assess the merits of these and other developments in gender inclusion in drug 
safety research, and of the Research Ethics Board [REB] system through which they are 
implemented.  In the second part we will analyze the role of the pharmaceutical industry in 
structuring health information and the way these activities undermine gender equity.  This 
analysis is undertaken to assess whether gender equity in clinical trials has been achieved, or is 
still an aspiration. 
 
II Canadian position on inclusion 
Context 
Proper inclusion in clinical trials requires representation in sufficient numbers to permit analysis 
of data of sub-populations such as women and men, and elderly women and men, and members 
of ethnic minorities.  To achieve the benefits of representation, it is necessary for researchers to 
perform the sub-sample analyses for each group in relation to the others.  As well, to achieve 
gender equity, researchers need to consider the data in light of social factors that inform the 
concept of gender.  These environmental and behavioural factors13 comprise the social 
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determinants of health, and include income and social status, physical environments, culture, and 
sex.14  The unique health status of poor aboriginal women living in remote locations provides 
stark evidence of the relevance and significance of these determinants.15  Social determinants of 
health affect the ways women and men use the health care system, view their health, use 
prescription medications, and participate in clinical trials.16  To further respect women’s 
interests, women need to be empowered to make their own decisions about participation in trials.  
Also, some trials should take place during pregnancy.  Finally, women should not be pressured to 
participate by the drug industry or physicians, or be made to undergo trials as a means of 
obtaining otherwise inaccessible care. 
 
Canada has taken a variety of steps to establish standards and organizations to implement its 
international commitments in the area of women’s health. This institutional framework provides 
the context for a discussion of gender inclusion in research and clinical trials in particular and 
gender equity in health more broadly.  Canada ratified the Convention on the Elimination of All 
Forms of Discrimination Against Women, article 12 of which requires the elimination of 
discrimination in the field of health and health care, with specific reference to pregnancy 
services.  In 1993, the Canadian government established the Bureau of Women’s Health within 
Health Canada (now referred to as the Bureau of Women’s Health and Gender Analysis).  The 
Bureau’s mission is to promote equitable health outcomes for women and men, boys and girls.    
In 1999 the Bureau published the Women’s Health Strategy, which focuses specifically on 
gender-based analysis, access and accountability.17  In 2000 Canada reiterated its 1995 
commitment to the Beijing Declaration at the United Nations and published Health Canada’s 
Gender-based Analysis Policy [GBA Policy], which provides an analytic framework within 
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which to assess how government policies, programs, and legislation contribute to gender equality 
and to more equitable health outcomes.18 The Bureau of Women’s Health and Gender Analysis 
describes GBA as using sex and gender to perceive social differences and contexts and to 
identify how these conditions affect health status and interactions with the health care system.19 
 
As an example, they discuss the clinical trials policy, stating that applying GBA reveals gender 
bias and raises questions about the scientific validity of studies, resulting in the policy now 
requiring inclusion of both sexes unless the drug is intended for use in only one sex.  The GBA 
Policy recognizes that a gender perspective is essential to health policy and notes that full 
integration of gender analysis into planning and operations is required.20 The Women’s Health 
Strategy provides the framework for integrating gender-based analysis into programs and 
policies.  The Strategy outlines 64 key activities to meet its goals.  One activity consists of 
monitoring the implementation of the inclusion guideline for women in clinical trials. 
 
The Women’s Health Bureau supports the Canadian Women’s Health Network [CWHN] and 
five Centres of Excellence for Women’s Health across the country.  The CWHN has suggested 
that a review of the Women’s Health Strategy would be timely, noting that in 2005 Health 
Canada told the Standing Committee on the Status of Women that it planned to review the 
Strategy.21  Olena Hankivsky, in her review for the CWHN of Canada’s progress on women’s 
health since the Beijing Declaration, concludes that progress has been made in the previous ten 
years, but that “much more work needs to be done to realize the federal government’s 
commitments to Beijing and Beijing+5, among other international obligations”.22  Hankivsky 
points to six specific problems, among them the lack of a formal mechanism to ensure gender-
based analysis in health research, the under-representation of women in health and science 
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careers, gender bias in research methods and priorities, and the government’s failure to regulate 
health matters in areas where it has the authority to do so, as it does with drug advertising.  In 
addition, she notes that while the Women’s Health Strategy had taken note of the need to be 
sensitive to diversity, it needs to take full account of the inequities experienced by women who 
are poor, disabled, aboriginal, or elderly.23 
      
Drug approval process 
The legislation governing drug approval is the Food and Drugs Act, a federal statute.24  The Act 
and the Food and Drug Regulations are silent on gender equity.25  In 1997, Health Canada issued 
a guideline on inclusion to apply to all clinical trials, Inclusion of Women in Clinical Trials.26  
The guideline asserts that, “[d]rugs should be studied prior to approval in subjects representing 
the full range of patients likely to receive the drug once it is marketed”.  The guideline also states 
that, “patients of both sexes should be included in the same trials in numbers adequate to allow 
detection of clinically significant sex-related differences in drug response” and further, that 
“[a]nalyses to detect the influence of sex should be carried out both for individual studies and in 
the overall integrated analysis of efficacy and safety.” 
The guideline’s stated intent is to “encourage the inclusion of women, especially women of 
child-bearing potential, at the earliest stages of drug development” so that sex-related differences 
may be identified early and taken into account in Phase III safety and efficacy trials, and to 
ensure that data will be available to inform physicians and patients about sex-related drug 
qualities. This point is significant since it is at the early stage of research that the 
pharmacokinetics and pharmacological effects are identified.  As the guideline notes, these 
differences might occur in dosage responses, maximum size of effect, or adverse effect risk.  The 
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guideline states that exclusion from early trials out of concern for fetal toxicity is not necessary 
because women can take adequate precautions against becoming pregnant and exposing a fetus 
to potential danger.27  According to the guideline, the decision of whether to enroll pregnant or 
lactating women in a particular trial needs to be individualized.  Risk should be assessed by 
patients, their doctors, the manufacturer, and REBs, with oversight by the Therapeutic Products 
Directorate.     
The guideline states the principle of inclusion in a forthright manner and develops the rationale 
for it.  Since the guideline lacks the legal force of a regulation or statute, however, it is 
comparatively weak.  In addition, its reasoning is undermined by its own wording which 
suggests a lack of willingness to enforce the guideline, since it is designed to “encourage” and 
“promote” inclusion.  The Minister of Health may reject an application to market a drug on the 
basis that it fails to meet the requirements of the Food and Drug Regulations or that the 
application does not contain sufficient information for the Minister to assess the safety of the 
drug or of the clinical trial.28  This provision applies to those drugs not yet licensed for marketing 
and to those approved drugs being assessed for new uses, formulations and combinations.  Since 
the inclusion guideline lacks the status of a regulation, it cannot be used directly to reject an 
application for failure to meet a regulation. Even though it is arguable that a lack of 
representation and analysis could provide the basis for Ministerial rejection on the basis of 
inadequacy of the information to assess the safety and efficacy of the drug or the clinical trial, 
only regulatory status for the inclusion principle would provide a clear and unequivocal basis for 
such a rejection.  
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Reviewers of the safety and efficacy of new drug submissions must follow a standard operating 
procedure, which normally requires gender-based analysis as an evaluation method in a number 
of instances.29  Applying the inclusion guidelines at this stage, reviewers consider how the 
clinical trial population represents the population to whom the drug will be marketed.  Where a 
drug is to be used by women it would be strongly recommended that it be tested on women.  A 
drug tested only on men, for example, might only be allowed to be marketed to men.30  Gender 
might also be considered for safety reasons if a drug is under consideration for a new indication 
or if a drug under a notice of compliance with conditions is to go through post-market testing.  
The procedure provides at paragraph 4, however, that “[d]eviations from this procedure may be 
acceptable, provided the deviations and their justification are documented in the assessment 
report.”  Further, the instructions are said to be “a guide for reviewers, but the inclusion or 
exclusion of information under a section is left to the scientific judgement and discretion of the 
reviewer.”31  Timing such review during the safety and efficacy evaluation heightens its potential 
to enforce gender inclusion policy.  Under the current legislation, the government has most 
power to effect changes during the approval process.  The Minister is authorized under the 
Regulations to withhold approval for failure to meet standards but once the drug has been 
approved for marketing, the Food and Drugs Act provides scant authority to require changes.  As 
Health Canada observes in its 2006 document, Blueprint for Renewal, “[i]ts [the Food and Drugs 
Act’s] authorities for compliance and enforcement, based on criminal law, are outdated and 
resource intensive, which limits the range of actions that can be taken, including appropriate 
sanctions and incentives.”32  Also, no systematic review mechanism to review the inclusion 
guideline had been put into place, in spite of the promise in the Women’s Health Strategy of 
Health Canada to monitor the inclusion policy for clinical trials.33  The government itself has not 
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reviewed the success or failure of its own policies on inclusion providing us little reason to be 
optimistic about their implementation.34 
 
The International Conference on Harmonisation [ICH] has brought together six parties (the 
governments and pharmaceutical organizations from Japan, the European Union, and the United 
States) and three observers (Canada, the World Health Organization, and the European Free 
Trade Association), with a view to harmonizing drug approval processes among countries that 
choose to incorporate ICH practices into their governing legislation.  As Health Canada states on 
its website, Canada has adopted and integrated the good clinical practice principles from the ICH 
Good Clinical Practice [ICH-GCP] guidelines into its 2001 regulations, though they do not have 
the force of law.35  Relying on the ICH-GCP guideline is problematic to some extent because of 
the absence of a national regulatory scheme to fill in gaps and the absence of a process to ensure 
respect for the guideline.36  The 2001 Canadian regulations contain no explicit reference to 
gender equity.  The regulatory impact statement analysis lists ICH guidelines that were to be 
adopted in Canada.37  These include Guideline E8 (General Consideration of Clinical Trials) 
stating the principle that the study population should represent the target population, as in the 
Canadian inclusion guideline - and requiring pharmacokinetic information for women in Phase I 
along with certain dose-response information to support drug registration.  Further, guidelines E3 
and M4E require sex-based identification of the patient population, analysis and critical 
assessment of the data by sex.38  The impact of these policies is softened, however, by opting out 
statements such as “if the size of the study permits”.39  As another example, the E6 (R1) Good 
Clinical Practice guideline currently states at 7.3.6, a provision relating to effects in humans, 
that, “[a] summary of information on the pharmacokinetics of the investigational product(s) 
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should be presented, including the following, if available…[p]opulation subgroups (e.g. gender, 
age…).”  Once again, the impact of this recommendation is limited by the words “should be 
presented” and “if available”. 
 
In March 2007, the Bureau of Women’s Health and Gender Analysis and the Policy 
Coordination Division of Health Canada convened a day long conference entitled “Context 
Matters: A Health Canada Symposium on Gender, Diversity and Clinical Trials”.  The meeting 
brought together officials from both the Health Policy and Health Products and Food branches of 
Health Canada as well as a number of speakers to consider issues of equity in clinical trials with 
an emphasis on achieving greater diversity on the basis of gender, ethnicity (including aboriginal 
populations) and age (including children and the elderly).  The conference organizers used the 
day long symposium as an opportunity to educate Health Canada officials about the importance 
of ensuring that gender and diversity considerations are included in the ongoing legislative, 
regulatory and policy review.  Numerous questions on gender and health were addressed.  One 
speaker, Yvonne Lefebrve, after reviewing the history of the representation of women in clinical 
trials, concluded by suggesting that the outstanding issues are: monitoring and evaluating the 
appropriate representation of women in clinical trials and determining whether there is 
compliance with current standards/regulations; the sex-based disaggregation of data; the need for 
policies regarding equity and conducting international clinical trials; the inclusion of pregnant 
women and the representation of diverse groups of women.  
 
Tri-Council Policy Statement, Ethical Conduct for Research Involving Humans 
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The TCPS was adopted following extensive negotiations among the three federally funded 
granting councils, in order to create a common standard for funded research, regardless of 
discipline.  The composition of REBs and their mandate to review and approve biomedical 
research involving humans and to conduct periodic reviews is set out in the Food and Drug 
Regulations.40  The structure and mandate of REBs are also specified in the TCPS, though in 
somewhat different terms.  Clinical trials must be approved by REBs as part of the Food and 
Drugs Act drug approval process.41  Although the Therapeutic Products Directorate has indicated 
that all clinical trials are to adhere to the TCPS, a question may be raised about whether this is 
enforceable.42  As Mark Hadskis has commented, “[d]etermining when a particular activity is 
captured by the TCPS is not always a straightforward matter.”43  The TCPS applies to any 
research, defined as systematic inquiry to prove facts, principles or generalizable knowledge that 
is directly or indirectly funded by the granting councils.  Also, following the requirements of the 
TCPS may be a term of private agreements among institutions or be a requirement of regulatory 
bodies.  Peer-reviewed journals and courts may also promote compliance with the policy 
statement.44  The TCPS does not apply in a general manner outside of these contexts.45  The 
TCPS is enforced mainly through the denial of funding to proposed research.  Rarely, an 
institution conducting approved and funded research which turns out to not to conform to TCPS 
requirements may be made to return funding.  
 
The TCPS contains one statement dealing primarily with gender equity: that “[w]omen shall not 
automatically be excluded from research solely on the basis of sex or reproductive capacity”.46  
In addition, where research is not specific to a group, Article 5.1(a) prohibits researchers from 
excluding subjects at the recruitment or research stage based on such attributes as culture, race, 
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disability, sex, and so on.  These provisions can only be described as weak and ineffectual.47  By 
prohibiting only the most egregious exclusions – automatic exclusion solely on sex or 
reproductive grounds - they permit even non-arbitrary sex-based exclusion.48  Similarly, 
exclusion is permitted when a “valid reason” is offered.  The provisions contain no requirement 
that samples contain sufficient numbers for sub-sample analysis to be carried out or that such 
sub-sample analysis be done.  An earlier version of these provisions contained stronger language 
which was “gutted” by the councils.49  Françoise Baylis, Jocelyn Downie and Susan Sherwin 
have described their reaction to the process: “To our surprise and dismay, the first official draft 
Code of Conduct for Research Involving Human Subjects reduced all of the above proposals to a 
single prescriptive clause that clearly sought to mask the gendered nature of the problem of 
exclusion and underrepresentation….”50        
 
REB review plays a central role in protecting patient safety in the Canadian system.  The Law 
Commission of Canada’s review of REB governance commented on the excessive and virtually 
total reliance on REBs to provide assurance of ethical compliance.51  No formal qualitative 
review or accreditation process for REBs exists at this time.  Health Canada noted this deficiency 
at the time the 2001 Food and Drug Regulations were put into place, and yet justified not placing 
more responsibility on REBs than they had already.52  Currently, the National Council on the 
Ethics of Human Research provides organizational oversight and has supported the 
implementation of a voluntary accreditation and certification system.53  Trudo Lemmens has 
argued in favour of federal oversight of REBs on the ground that REBs have a public mandate to 
protect research subjects and the public.54  The variations in the legal force of the multiple laws, 
international documents, and guidelines, along with the differences in law applying within 
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provincial and territorial jurisdictions, add to the complexity of the task of evaluating proposed 
research.  The increasing number of multi-site clinical trials and the specialized nature of 
research create other demands on local REBs.  Kathleen Cranley Glass has described the 
structure in these terms: “[t]he current system of research governance is fragmented and 
decentralized, without a consistent, accountable, and transparent system of ethics review.  We 
have yet to establish a comprehensive, uniform set of standards or structure for review that 
would apply to all research involving humans.  There are no viable systems of education, 
accreditation, or monitoring.”55 
 
One significant drawback of the REB system in Canada is the lack of monitoring of clinical trials 
and research.56  Although monitoring clinical trials is part of the REB mandate,57 many 
institutions provide insufficient support to carry out oversight after the protocol has been 
approved. 58  The Therapeutic Products Directorate’s 2002 Inspection Strategy for Clinical Trials 
estimated that the Therapeutic Products Directorate would inspect only two per cent of clinical 
trials involving human subjects,59 a rate described as the international norm.60   
 
Drug safety 
The problems in the area of REB review are compounded by the known deficiencies in the 
system of drug approval and oversight.  Health Canada has reviewed the drug approval process 
and incorporated many of its findings into two documents, Blueprint for Renewal [Blueprint]61 
and the revised version following consultation, Blueprint for Renewal II [Blueprint II].62  Most 
recently, the Minister of Health has introduced a Bill that, if passed into law, will notably change 
Canada’s drug approval process. 63      
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A brief consideration of issues facing the drug approval and oversight system in the United 
States is helpful.  In 2006, the United States Government Accountability Office [GAO], the 
investigative arm of Congress, identified serious problems in the FDA’s oversight of safety once 
the product reaches the market.64 The 2006 GAO Report considers oversight to have been 
compromised by lack of tracking of information about safety issues, lack of criteria to tell both 
when safety decisions should be taken and what decisions to take, weak data, and poor decision-
making processes.  In other words, the most powerful drug regulation agency in the world does 
not know when or how to make decisions about the safety of drugs.  Furthermore, the GAO 
report notes that the FDA lacks legal authority in most instances to order a company to carry out 
further tests of safety once its product is on the market.  
 
The Institute of Medicine [IOM] released its much-anticipated report on drug safety soon after, 
in September 2006.65  This report identifies significant impairments in the drug safety system 
resulting from severe funding constraints which weakened scientific analysis of drug safety, a 
less than optimal organization culture, and inadequate regulatory authority, most notably with 
respect to enforcement. The IOM report includes a lengthy list of recommendations directed to a 
fundamental restructuring of the drug approval process.  Among the proposals that would have a 
significant impact if adopted in Canada are: the limited licensing of new drugs, similar to the 
progressive licensing framework supported in Blueprint and Blueprint II; labelling requirements 
to warn consumers that the product is a new drug; an advertising ban for new drugs; mandatory 
registration of clinical trial results to improve access to drug safety information; and the authority 
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to withdraw the product from the market, impose fines and issue injunctions for failure to meet 
obligations to carry out safety studies.   
 
While we need to exercise caution in generalizing about drug approval systems, it is clear that 
any drug safety system that is broken in such fundamental ways lacks the ability to effectively 
promote public safety and health.  The deficiencies in drug safety inevitably have an impact on 
the ways data on women’s health are gathered, assessed and used.  Reforms directed to inclusion 
and gender equity will be effective only with a broad overhaul of the drug safety system.  In 
Canada, the weak “guarantees” of a guideline and a virtually useless research standard are 
unlikely to have much impact in a system suffering from its own identified weaknesses.  
 
Canada’s recently introduced Bill to amend the Food and Drugs Act, if enacted, will constitute a 
significant restructuring of the drug approval process.  The Bill addresses many of the concerns 
noted in Blueprint and Blueprint II by developing a progressive licensing framework for drug 
approval, setting a new standard for risk assessment, and providing means to secure more 
information about product risks.  Under the new framework, the Minister is given the power to 
grant market approval with conditions, to amend those conditions following notice and a hearing, 
to suspend or revoke a clinical trial authorization in particular circumstances, and to grant 
licenses for limited uses of drugs.  The new standard to be met for drug approval is Ministerial 
satisfaction that the benefits provided by the drug outweigh the risks.  If adopted, the risk-benefit 
standard will mark a change from a more precautionary principle that requires standards to be 
met after technical review.  The Bill significantly expands the Minister’s power over regulation 
and reporting in the post-market period.  The Minister will have the power to compel the holder 
 16 
of a market authorization or establishment licence to compile information, conduct tests or 
studies or monitor experience to obtain additional information relating to the product’s effects on 
health or safety or to report this information to the Minister.  As well, subject to the Regulations, 
the Minister may compel production of information under their control that is considered 
necessary to administer the Bill.  Significantly, the Bill enables the Minister to require any 
labelling necessary to prevent injury to health, a reassessment of a therapeutic product within a 
set time, and public disclosure of information about risks and benefits. 
 
Bill C-51 does not directly take up issues of gender equity or sub-population testing, although 
those issues may be addressed in the regulations and through the related initiatives being taken 
by the government.  Blueprint highlights the need to emphasize specific populations in research 
and policy, noting possible differences in drug responses to drugs and the need to address 
specific needs, 66  Even so, the Bill has implications for achieving gender equity in clinical trials 
and drug safety more generally.  For one thing, though progressive licensing can be used to 
ensure drug safety, it can also be used to approve drugs for marketing more quickly.  This latter 
possibility may create tension with the goal of promoting safety.  Blueprint II indicated that the 
government would consider early access mechanisms in its progressive licensing framework to 
address the particular therapeutic or health needs of specific populations.67  Earlier availability 
can mean that a drug is available earlier to a broader and more representative population than 
would have been possible at that stage under the current system, but without necessarily having 
completed clinical trials on the full range of populations who will use it.  Only if post-market 
testing is actually achieved will this change be successful for the entire population who will be 
exposed to the drug.  With respect to risk management, Women and Health Protection, in their 
 17 
comment on Blueprint, state that an emphasis on “managing risk” would replace the 
precautionary principle of health protection. 68 While under the new Bill it is the applicant that 
must establish that this risk-benefit standard is met, the terms will be subject to wide 
interpretation.  Therefore, without some guidance, Ministerial decision-making on this issue 
raises the possibility of the politicization of the drug approval process.  Because the drug 
regulation system operates within government rather than through an arm’s length agency, the 
prospect of politicization is real.  Finally, with respect to access to therapeutic information or 
disclosure, the language of the Bill is permissive, stating that the Minister “may” disclose to the 
public information about the risks or benefits associated with a therapeutic product.  These 
shortcomings may serve to exacerbate whatever inequalities women experience in the clinical 
trial/drug safety context. 
 
In contrast to the above concerns, increased oversight in the post-market period greatly favours 
drug safety and efficacy for the broader range of groups that will use the drugs once marketing 
commences.  Significant improvements in the availability and accessibility of information may 
be achieved through the new powers to be attributed to the Minister.  Specifically, the Minister 
will be able to acquire information through the creation of a publicly accessible register of 
information, through the potential revealing of confidential business information in certain 
circumstances, and through mandatory reporting of adverse drug reactions [ADRs] by prescribed 
institutions.  The promotional aspects of information distribution are addressed in several 
changes addressing criteria for fraud or deception and in a change prohibiting advertisement 
unless authorized by the regulations, although the Bill does not address directly the issue of 
direct-to-consumer advertising.  Strengthened powers of administration and enforcement, 
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expanded powers for inspectors, enhanced remedies for offences, including injunctions, more 
realistic fines and imprisonment, application of offences to directors and other persons who are 
parties within corporations, and the requirement that sentencing take into account the harm or 
risk and vulnerability of consumers are all likely to enhance health information and safety.  The 
impact of the legislation will depend though on the regulations and on the will of the Minister. 
 
Common law    
While we are unable to explore this issue in detail, it is worth raising the question of whether a 
tort lawsuit could be successful based on failure to test drugs on women.69  It can be argued that 
an action targeting testing inadequacies would provide an important impetus to manufacturers to 
include women in their studies, countering the fears of litigation that led drug manufacturers to 
exclude women. Litigation on this basis might help persuade the industry that it is in their 
interest to include representative samples and to analyze these data.  At the same time, one must 
ask whether testing drugs on women could itself lead to legal liability.  Ellen Wright Clayton has 
suggested not, writing, “the risk of incurring liability during the early stages of drug investigation 
is actually quite small whereas the potential for substantial liability is much greater once a 
fetotoxic drug enters widespread use.”70   
 
Summary 
An overview of Canada’s position on gender inclusion in clinical trials reveals numerous 
achievements, yet also shortcomings which leave ample room for further development.  
Women’s activism and international developments in the United Nations and the United States 
have caused the Canadian government to address the issue of how to include women in clinical 
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trials so as to come closer to achieving gender equity in health.  The government and affiliated 
groups have produced policy documents and guidelines.  Though perhaps commendable, these 
guidelines lack the force of law and do not even attempt to require conduct or check to see 
whether goals have been met.  These limitations are exacerbated by the drug safety and research 
ethics board context within which the guidelines operate.  The proposed amendments to the 
federal food and drug legislation holds out the promise of increased amounts of health 
information and greater control by government over the process; however, it is too soon to say 
whether the move to progressive licensing and a risk-benefit standard will enhance or diminish 
gender equity.  The mechanisms chosen to achieve gender equity remain outside the legislative 
framework.  Finally, while the threat of tort litigation might induce drug developers to increase 
testing of their products on women, this potential cause of action remains untested.  The next 
section of this paper looks more closely at the role of the pharmaceutical industry in gender 
equity in health. 
 
III The role of the pharmaceutical industry in gender equity in health 
One aspect of gender equity in health is the creation of health information that can serve to 
improve women’s health.  For this reason, the way information is constructed and transmitted 
needs to be assessed.  Information collected about women’s reactions to drugs is gathered and 
filtered through the pharmaceutical company’s promotional lens.  The drug industry creates 
knowledge about their products in a literal and scientific sense through the process of drug 
research, through the presentation of results to the regulator, through publication of research 
results in journals, and through promotional activities.71  We have become acutely aware of the 
dramatic breakdown in the transmission of reliable information through these channels.  For 
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example, the cox-2 inhibitor Vioxx was portrayed as a safe and effective means of controlling 
pain for arthritis patients and its risks were obscured, as was demonstrated in the Report prepared 
by Representative Henry Waxman for the U.S. House Committee on Government Reform, which 
provided a rare glimpse of the activities of drug sales representatives (detailers) in their 
interactions with doctors.72  Similarly, the antidepressant paroxetine, known as Paxil in North 
America and Seroxat in Great Britain, was being used extensively among adolescents until the 
BBC program Panorama aired the first in its series of post-market reports on the drug which 
stimulated an outpouring of evidence of the significant risk of suicide and suicidal ideation.73 
 
Sources that appear to be neutral and unbiased, such as government advisory panels and peer-
reviewed journals, have had underlying conflicts of interest unmasked.74  As John Abramson 
notes in Overdosed America, drug companies may withdraw advertisements from a journal if 
their needs are unmet, while,“[t]he journals benefit from the publicity gained from publishing 
large drug company-sponsored studies.  This increases the value of their advertising and enables 
them to sell back to the drug companies reprints of articles, which the drug companies then 
distribute as marketing tools to doctors.”75  Corruption of the information-distribution process 
has occurred through ghost-writing of articles by industry, industry-funded patient advocacy 
groups, sponsored conferences and selective publication of results.76  As the integrity of the 
process is jeopardized and health information is skewed, the accuracy of the information 
applying to women comes into question and women’s health is affected.          
 
Promotion by the pharmaceutical industry creates diseases that can be cured by pills – “selling 
sickness” or “disease-mongering”, in other words.77  Pharmaceutical products create the image of 
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an answer to a “disease” that is aptly described as industry-created, examples being social 
anxiety disorder or baldness.  The dual myths of the need for intervention and of the need for a 
particular drug’s intervention are created through these images.78  Intervention through dealing 
with underlying problems linked to the social determinants of health has no appeal to the drug 
industry.  Poverty, chronic joblessness, social environments, gender and culture, and a range of 
other social determinants influence health and access to the health system.  Buying into the 
pharmaceutical model – interventionist, individualistic, technological – leads individuals and 
governments away from the collective, community-focused and preventive public health 
solutions.  The social determinants of health approach is linked to gender-based analysis, which 
helps us to understand how the experiences of women and men are different and similar and how 
health status, health needs and health care utilization differ.79  Pharmaceutical intervention 
ignores these links. 
 
These flaws in the construction and transmission of health information have an impact on gender 
equity.  Distortions in data diminish the impact of gender inclusion policies.  Gender 
representation in research is essential to creating knowledge about the impact of drugs on the 
experiences of women and men.  Unless the research is done, and the results accurately 
conveyed to all who need them, the impact on women’s health will likely be unjust. 
 
ADR data need be comprehensively examined to determine whether and how gender is a 
factor.  Women have been found to experience more ADRs than men.  This result is 
sometimes attributed to women’s greater exposure to health professionals and higher level 
of drug-taking.  Bates and Leape have reported on studies that indicate that women have a 
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rate of ADRs 50% higher than men and consider whether these rates may be affected not 
only by the greater frequency of medical attention and drugs but also by the periods of 
women’s lives when pharmacokinetics are affected: menarche, pregnancy and delivery, 
lactation, and menopause. 80 Could it also result from lack of knowledge about the impact 
of drugs on women, or on particular groups of women?  Beard and Lee81 have noted that, 
“[i]n general, women appear to be at greater risk of ADRs than men.  Female patients 
appear to have a 1.5-1.7-fold greater risk of developing an ADR.82  The reasons for this are 
not entirely clear, but include gender-related differences in pharmacokinetic, 
immunological and hormonal factors, as well as differences in the pattern of medicine use.”  
Elderly women, who make up the majority of elderly people, take multiple prescriptions 
whose interaction effects remain largely unstudied.  Boxer and Shore have described the 
impact in these terms: “[a]dverse drug reactions occur about twice as often in older than 
younger patients…Risk of an adverse drug reaction increases with greater severity of 
illness, multiple comorbidities, smaller body size, changes in hepatic and renal metabolism 
and excretion, and prior drug reactions.” 83 Studies demonstrate the lack of inclusion and 
representation of those who will use drugs, with specific reference to elderly patients.  One 
study notes, “NSAIDs are commonly used in elderly people because of the high prevalence 
of musculoskeletal disorders, especially in women.  However, in the major drug trials 
evaluating NSAIDs, only 2.1% of patients were 65 years of age or over and less than 0.1% 
were over 75.  In practice, elderly people are among the largest users of drugs and have the 
highest incidence of serious drug-related side effects.”84 
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In light of these and similar flaws in gathering health information, we have several 
recommendations for change in the pharmaceutical industry and in regulatory oversight.  First, 
knowledge about drug reactions needs to be collected in a broad and systematic manner.  The 
Canadian system, like the American, collects drug information through mandatory reporting by 
drug companies to government and through voluntary reporting by doctors and hospitals.  It is 
possible for Canadian consumers to report directly online, but the weight given to self-reporting 
is not indicated.  When the BBC program Panorama ran the first of its series of programs on the 
antidepressant Seroxat, they received 1374 emails, as well as letters and 862 website 
communications from viewers who described their own experiences with the drug.  An analysis 
of these results concluded that the picture created by reading the reports provided more complete 
data, including reports of suicides that had not been reported to the British authorities, and 
contained the context of the events so that the data could be evaluated and the impact on health 
more realistically assessed.85  Another study looks at the printouts of reports from the Yellow 
Cards submitted by physicians and other health professionals over 12 years (1990-2002) on 
adverse effects of paroxetine.  Comparing the professional reports with the reports from patients 
in the previous study, the authors observe that patient reports “communicate essential 
information which professional reporters can never be expected to provide.  In this case, patients 
provided reports that were much richer in their descriptions of behavioural phenomena and 
feelings than the YC [Yellow Card] reports and often much better at explaining the nature, 
significance and consequences of adverse drug effects.  Patient reports convert the more 
technical terms that professionals use into understanding.”86 
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The voluntary reporting system results in significant underreporting of adverse events, at a level 
estimated at 10 per cent of what had been experienced and even the study of the mandatory 
Yellow Card system found a significant degree of underreporting.87  Patient safety is jeopardized 
when early identification of risks is undermined, particularly in the immediate post-market 
period when the number of individuals exposed to drugs is significantly increased and the drug is 
provided to people on whom the drug was not tested.  As women experience more ADRs than 
men, this risk falls disproportionately on women.  While Canada’s proposed legislative changes 
would require ADR reporting by prescribed classes of institutions prescribed by the regulations, 
this is only a first step.   
 
Adverse effects data-gathering must become much more efficient, accurate and contextual in 
order to protect public health.  Health Canada has suggested several approaches to remedy the 
current deficiencies, including requiring industry to make a submission prior to approval of their 
plans for pharmacovigilance in the post-market period; establishing the authority under the 
Regulations to require post-market studies; collaborating to develop head-to-head comparison 
studies and large observational studies; addressing under-reporting; developing active 
surveillance systems; and increasing government’s capacity to assess safety signals.88  Another 
way to achieve this goal is by paying attention to and recording patient descriptions of adverse 
reactions.  The deficiencies of the adverse effect reporting system in Canada have been on Health 
Canada’s radar for decades and it is time for these useful suggestions to be fully assessed and 
implemented.   
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Next, reliable sources of information that are fully independent of the industry are needed to 
maintain the integrity of the public process and restore confidence in the system.  An 
independent evaluator of information is also required to inquire into such issues as gender 
inclusion and drug advertising.  Having industry pay to have clinical trial data evaluated in the 
process of drug approval in the United States has led to speedy trials, but these have been linked 
to a higher level of drug recalls.  Eight out of ten drugs withdrawn by the FDA between 1997 and 
2000 – a very high rate of withdrawal in itself – had greater health risks for women.89   
 
Also, doctors and patients need to be made fully aware of the populations on whom the drug has 
been tested and the results.90  Access needs to be given to data submitted during the approval 
process, and unless it is, doctors and patients will lack information that is vital to decision-
making.91 To give meaningful access, the government would need to require release of data from 
companies concerned about revealing trade secrets, as in the proposed legislation. 92   
 
Finally, a strong need exists to monitor the inclusion of representative populations through an 
independent entity.  Such an entity should also review drug advertising to prevent the use of 
stereotypes and to prevent promotion from undermining disclosure.  Advertisements directed to 
prescribing professionals need to be subject to enhanced scrutiny on this basis, supported by 
regulations.  Direct-to-consumer advertising, ostensibly prohibited in Canada, needs to be 
prohibited in fact.  An independent agency could assist in monitoring the distribution of 
broadcast, print and on-line ads.  Several authors have suggested that an independent entity of 
this sort should review the clinical trials process as a whole.93 
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IV. Conclusion 
The Canadian government has indicated its strong support for gender equity through its policy 
statements, institutional structures and guidelines.  At the same time, it has not fully translated 
these aspirations into concrete achievements, either by enacting legislation or through 
administrative oversight.  In considering the ways the pharmaceutical industry presents drug 
information and in the over-emphasis on research ethics board review as the mechanism for 
monitoring the ethical aspects of drug trials, it is apparent that there is room for improvement in 
achieving the aspirations of the inclusion policy.  We have pointed to the need for specific 
reforms in the areas of drug approval and the creation of knowledge about drugs as a means to 
realize these goals.  Gender inclusion has significant health rewards for women.  Achieving 
inclusion requires a commitment to using effective legislative and administrative mechanisms, 
including those that will enhance safety and the provision of health information, to achieve the 
benefits of the inclusion commitment. 
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